[HTML] springer.comFull View

[HTML][HTML] miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee, MJ Calkins… - Breast Cancer …, 2017 - Springer
Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and
viable targeted therapeutics. Moreover, chemotherapy only produces 20–30% pathologic …
被引用次数：174 相关文章

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.

HY Li, JL Liang, YL Kuo, HH Lee… - Breast Cancer …, 2017 - search.ebscohost.com
Abstract < bold> Background: </bold> Triple negative breast cancer (TNBC) lacks
both early detection biomarkers and viable targeted therapeutics. Moreover, chemotherapy …
[HTML] nih.gov

[HTML][HTML] miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee… - Breast Cancer …, 2017 - ncbi.nlm.nih.gov
Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and
viable targeted therapeutics. Moreover, chemotherapy only produces 20–30% pathologic …

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee, MJ Calkins… - Breast Cancer …, 2017 - go.gale.com
Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and
viable targeted therapeutics. Moreover, chemotherapy only produces 20-30% pathologic …

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.

HY Li, JL Liang, YL Kuo, HH Lee… - Breast Cancer …, 2017 - europepmc.org
Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and
viable targeted therapeutics. Moreover, chemotherapy only produces 20-30% pathologic …
[PDF] academia.edu

[PDF][PDF] miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee, MJ Calkins… - 2017 - academia.edu
Background: Triple negative breast cancer (TNBC) lacks both early detection biomarkers
and viable targeted therapeutics. Moreover, chemotherapy only produces 20–30 …

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee… - Breast cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and
viable targeted therapeutics. Moreover, chemotherapy only produces 20-30% pathologic …
[HTML] biomedcentral.com

[HTML][HTML] miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo… - Breast Cancer …, 2017 - breast-cancer-research …
Triple negative breast cancer (TNBC) lacks both early detection biomarkers and viable
targeted therapeutics. Moreover, chemotherapy only produces 20–30% pathologic complete …

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee… - Breast Cancer …, 2017 - researchoutput.ncku.edu.tw
Background: Triple negative breast cancer (TNBC) lacks both early detection biomarkers
and viable targeted therapeutics. Moreover, chemotherapy only produces 20-30 …

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

HY Li, JL Liang, YL Kuo, HH Lee… - Breast Cancer …, 2017 - nckur.lib.ncku.edu.tw
Background: Triple negative breast cancer (TNBC) lacks both early detection biomarkers
and viable targeted therapeutics. Moreover, chemotherapy only produces 20–30 …